BioCryst Launches ORLADEYO® (berotralstat) in Ireland | Taiwan News | Nov. 18, 2024 15:00 The most common adverse reactions (≥10% and higher than placebo) in patients receiving ORLADEYO were abdominal pain, vomiting, diarrhea, back pain, … Source: back pain
